Biolase Inc

Find Ratings Reports
BIOL : NASDAQ : Health Care
$1.38 -0.017 | -1.2%
Today's Range: 1.35 - 1.45
Avg. Daily Volume: 77600.0
04/27/17 - 1:04 PM ET

Financial Analysis


BIOLASE INC's gross profit margin for the fourth quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not. BIOLASE INC has average liquidity. Currently, the Quick Ratio is 1.05 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has decreased by 11.47% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)13.7614.52
EBITDA ($mil)-3.84-1.98
EBIT ($mil)-4.11-2.28
Net Income ($mil)-4.43-2.46


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)9.1811.9
Total Assets ($mil)41.9442.25
Total Debt ($mil)0.160.79
Equity ($mil)22.0724.93


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin41.2440.08
EBITDA Margin-27.91-13.66
Operating Margin-29.9-15.67
Sales Turnover1.241.15
Return on Assets-36.64-47.99
Return on Equity-79.56-81.35
Debt Q4 FY16 Q4 FY15
Current Ratio1.892.3
Debt/Capital0.010.03
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)67.5758.23
Div / share0.00.0
EPS-0.07-0.04
Book value / share0.330.43
Institutional Own % n/a n/a
Avg Daily Volume141856.089171.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 3.92 indicates a premium versus the S&P 500 average of 2.99 and a discount versus the industry average of 4.93. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. After reviewing these and other key valuation criteria, BIOLASE INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BIOL NM Peers 44.36   BIOL NM Peers 26.92

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

BIOL's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

BIOL's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BIOL NM Peers 32.13   BIOL NA Peers 1.15

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

BIOL's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BIOL 3.92 Peers 4.93   BIOL 14.71 Peers 99.98

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BIOL is trading at a discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, BIOL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BIOL 1.67 Peers 4.94   BIOL 6.87 Peers 14.96

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BIOL is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BIOL significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades